SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
15.68 EUR
-0.16 (-1.01%)
Overall 1SXP gets a fundamental rating of 6 out of 10. We evaluated 1SXP against 20 industry peers in the Life Sciences Tools & Services industry. 1SXP scores excellent on profitability, but there are some minor concerns on its financial health. 1SXP has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1SXP was profitable.
1SXP had a positive operating cash flow in the past year.
Each year in the past 5 years 1SXP has been profitable.
In the past 5 years 1SXP always reported a positive cash flow from operatings.
1.2 Ratios
1SXP has a better Return On Assets (9.61%) than 90.00% of its industry peers.
The Return On Equity of 1SXP (17.02%) is better than 90.00% of its industry peers.
With an excellent Return On Invested Capital value of 13.92%, 1SXP belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
1SXP had an Average Return On Invested Capital over the past 3 years of 15.68%. This is significantly above the industry average of 9.25%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.02% | ||
| ROIC | 13.92% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
1.3 Margins
Looking at the Profit Margin, with a value of 15.06%, 1SXP belongs to the top of the industry, outperforming 85.00% of the companies in the same industry.
In the last couple of years the Profit Margin of 1SXP has remained more or less at the same level.
The Operating Margin of 1SXP (19.46%) is better than 80.00% of its industry peers.
1SXP's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 33.73%, 1SXP is doing worse than 65.00% of the companies in the same industry.
1SXP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.46% | ||
| PM (TTM) | 15.06% | ||
| GM | 33.73% |
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1SXP is creating value.
1SXP has about the same amout of shares outstanding than it did 1 year ago.
1SXP has a worse debt/assets ratio than last year.
2.2 Solvency
1SXP has a debt to FCF ratio of 1.72. This is a very positive value and a sign of high solvency as it would only need 1.72 years to pay back of all of its debts.
1SXP has a better Debt to FCF ratio (1.72) than 100.00% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that 1SXP is not too dependend on debt financing.
1SXP has a Debt to Equity ratio of 0.09. This is amongst the best in the industry. 1SXP outperforms 95.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.72 | ||
| Altman-Z | N/A |
ROIC/WACC1.63
WACC8.52%
2.3 Liquidity
A Current Ratio of 1.57 indicates that 1SXP should not have too much problems paying its short term obligations.
The Current ratio of 1SXP (1.57) is better than 80.00% of its industry peers.
1SXP has a Quick Ratio of 1.17. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of 1SXP (1.17) is better than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
1SXP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.00%.
Measured over the past years, 1SXP shows a quite strong growth in Earnings Per Share. The EPS has been growing by 14.04% on average per year.
1SXP shows a small growth in Revenue. In the last year, the Revenue has grown by 2.86%.
The Revenue has been growing by 13.84% on average over the past years. This is quite good.
EPS 1Y (TTM)-3%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-3.23%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
3.2 Future
The Earnings Per Share is expected to grow by 11.14% on average over the next years. This is quite good.
Based on estimates for the next years, 1SXP will show a small growth in Revenue. The Revenue will grow by 7.59% on average per year.
EPS Next Y2.46%
EPS Next 2Y7.83%
EPS Next 3Y9.93%
EPS Next 5Y11.14%
Revenue Next Year2.11%
Revenue Next 2Y5.22%
Revenue Next 3Y6.87%
Revenue Next 5Y7.59%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 16.16, which indicates a correct valuation of 1SXP.
1SXP's Price/Earnings ratio is a bit cheaper when compared to the industry. 1SXP is cheaper than 80.00% of the companies in the same industry.
1SXP is valuated rather cheaply when we compare the Price/Earnings ratio to 26.34, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 13.62, the valuation of 1SXP can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 90.00% of the companies listed in the same industry.
1SXP's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.56.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.16 | ||
| Fwd PE | 13.62 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1SXP indicates a somewhat cheap valuation: 1SXP is cheaper than 80.00% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 46.96 | ||
| EV/EBITDA | 9.12 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of 1SXP may justify a higher PE ratio.
PEG (NY)6.57
PEG (5Y)N/A
EPS Next 2Y7.83%
EPS Next 3Y9.93%
5. Dividend
5.1 Amount
With a yearly dividend of 0.87%, 1SXP is not a good candidate for dividend investing.
In the last 3 months the price of 1SXP has falen by -25.46%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 0.71, 1SXP pays a bit more dividend than its industry peers.
With a Dividend Yield of 0.87, 1SXP pays less dividend than the S&P500 average, which is at 2.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.87% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
16.40% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.4%
EPS Next 2Y7.83%
EPS Next 3Y9.93%
FRA:1SXP (12/9/2025, 12:19:20 PM)
15.68
-0.16 (-1.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners22.93%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.36B
Revenue(TTM)975.68M
Net Income(TTM)146.90M
Analysts80
Price Target28.59 (82.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.87% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.4%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-1.05%
Max EPS beat(2)5.48%
EPS beat(4)1
Avg EPS beat(4)-5.25%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)4
Avg EPS beat(8)6.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)1.75%
Revenue beat(4)1
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.61%
PT rev (3m)-4.36%
EPS NQ rev (1m)0.85%
EPS NQ rev (3m)0.85%
EPS NY rev (1m)-0.76%
EPS NY rev (3m)-2.08%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)-0.2%
Revenue NY rev (3m)-1.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.16 | ||
| Fwd PE | 13.62 | ||
| P/S | 2.42 | ||
| P/FCF | 46.96 | ||
| P/OCF | 11.6 | ||
| P/B | 2.74 | ||
| P/tB | 2.83 | ||
| EV/EBITDA | 9.12 |
EPS(TTM)0.97
EY6.19%
EPS(NY)1.15
Fwd EY7.34%
FCF(TTM)0.33
FCFY2.13%
OCF(TTM)1.35
OCFY8.62%
SpS6.48
BVpS5.73
TBVpS5.53
PEG (NY)6.57
PEG (5Y)N/A
Graham Number11.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.02% | ||
| ROCE | 17.02% | ||
| ROIC | 13.92% | ||
| ROICexc | 14.45% | ||
| ROICexgc | 14.86% | ||
| OM | 19.46% | ||
| PM (TTM) | 15.06% | ||
| GM | 33.73% | ||
| FCFM | 5.15% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
ROICexc(3y)16.18%
ROICexc(5y)17.77%
ROICexgc(3y)16.78%
ROICexgc(5y)18.78%
ROCE(3y)19.2%
ROCE(5y)20.87%
ROICexgc growth 3Y-8.59%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.46%
ROICexc growth 5YN/A
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.72 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 203.46% | ||
| Cap/Sales | 15.71% | ||
| Interest Coverage | 11.82 | ||
| Cash Conversion | 76.76% | ||
| Profit Quality | 34.23% | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | N/A |
F-Score5
WACC8.52%
ROIC/WACC1.63
Cap/Depr(3y)291.84%
Cap/Depr(5y)279.9%
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.98%
Profit Quality(5y)27.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-3%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-3.23%
EPS Next Y2.46%
EPS Next 2Y7.83%
EPS Next 3Y9.93%
EPS Next 5Y11.14%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
Revenue Next Year2.11%
Revenue Next 2Y5.22%
Revenue Next 3Y6.87%
Revenue Next 5Y7.59%
EBIT growth 1Y12.08%
EBIT growth 3Y18.37%
EBIT growth 5YN/A
EBIT Next Year46.87%
EBIT Next 3Y21.99%
EBIT Next 5Y18.79%
FCF growth 1Y-27.75%
FCF growth 3Y33.55%
FCF growth 5YN/A
OCF growth 1Y-5.4%
OCF growth 3Y19.45%
OCF growth 5YN/A
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.
What is the valuation status of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for SCHOTT PHARMA AG& CO KGAA?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for 1SXP stock?
The Price/Earnings (PE) ratio for SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 16.16 and the Price/Book (PB) ratio is 2.74.
Is the dividend of SCHOTT PHARMA AG& CO KGAA sustainable?
The dividend rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 3 / 10 and the dividend payout ratio is 16.4%.